Offer Request Form

Order list is empty

Shikari® (S-ATC) Anti-Cetuximab ELISA

Enzyme immunoassay for the qualitative determination of specific antibodies to  Cetuximab (Erbitux®) in human serum and plasma. 

This kit has been especially developed for the qualitative determination of Cetuximab in serum and plasma samples.

Cetuximab was associated to the development of anti- Cetuximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug. This might lead to severe complications. The Matriks Biotek SHIKARI® Antibody to Cetuximab ELISA Kit can be efficiently used for monitoring anti- Cetuximab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti- Cetuximab antibodies.. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary. 

All SHIKARI® ELISA kits are suitable for biosimilar work. 

All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.

For technical inquiry, please contact techsupport@matriksbiotek.com

Required Volume (µl) 20
Total Time (min) 140
Sample Serum, plasma
Sample Number 96
Detection Limit (ng/mL) +/-
Spike Recovery (%) -
Shelf Life (year) 1
Assay type Qualitative
Species Reactivity Human
Storage conditions Store at +4°C. Please refer to protocols.
Shipping conditions At room temperature
# File Action
Instructions For Use Download
Safety Data Sheet (SDS) Download

Publications with this drug

# File Action
Peña-Cabia, Silvia, et al. "Assessment of exposure-response relationship for cetuximab in patients with metastatic colorectal cancer and head and neck cancer." Farmacia Hospitalaria 46.1 (2022): 21-26. Visit Link
Zhang, Jinhua, et al. "sRNA-based screening chromosomal gene targets and modular designing Escherichia coli for high-titer production of aglycosylated immunoglobulin G." ACS Synthetic Biology 9.6 (2020): 1385-1394. Visit Link
Zhang, Jinhua, et al. "Synthetic sRNA‐based engineering of Escherichia coli for enhanced production of full‐length immunoglobulin G." Biotechnology Journal 15.5 (2020): 1900363. Visit Link
柴田海斗. "Simple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin." (2019). Visit Link
Peña Cabia, Silvia. "Evaluación de la relación exposición-respuesta de bevacizumab y de cetuximab en cáncer colorrectal metastásico y de cetuximab en cáncer de cabeza y cuello." (2022). Visit Link